F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer (PRECHOL)
F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer Treated by Abiraterone Acetate or Enzalutamide
Sponsor: University Hospital, Grenoble
Terminated
enrollment default
Other terminated trials from University Hospital, Grenoble
Other Castration-resistant Prostate Cancer trials with similar outcome
This PHASE2/PHASE3 trial investigates Castration-resistant Prostate Cancer and is currently terminated or withdrawn. University Hospital, Grenoble leads this study, which shows 5 recorded versions since 2013 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2_PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2_PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2_PHASE3
First recorded
Dec 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University Hospital, Grenoble
For direct contact, visit the study record on ClinicalTrials.gov .